Radium-223 (Xofigo) Induced Immunity in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Radium-223 is a type of radioactive drug that is routinely given to prostate cancer patients. It emits what is called “high-LET” radiation, which scientists suspect may encourage the body to rally its own immune defenses against cancer, a process known as “induced immunity.”
This study is not designed to treat patients, but to learn more about how induced immunity works. A patient must already be planning with his doctor to receive six infusions of Radium-223 over a six month period as part of his treatment.
Once routine Radium-223 treatment begins, subjects will have blood drawn during infusion visits at the Nuclear Medicine clinic (200 Medical Plaza, B-Level) or at the Clark Urology Clinic (200 Medical Plaza, Suite 140). Blood draws will occur at the following time points:
Subjects will not learn of the results of these blood tests.
For More Detailed Information Contact:
Nicholas Nickols, M.D., Ph.D., Principal Investigator 310-825-9771
Colleen Mathis, Study Coordinator 310-794-2731
UCLA Department of Radiation Oncology 310-825-6577